March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial ...

Shares of OptiNose (OPTN) have gained 58.6% over the past four weeks to close the last trading session at $9.15, but there could still be a solid upside left in the stock if short-term price ...

Shares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek Pharmaceuticals, a private biotech. This deal will add OPTN’s approved ...

Claim your 7-day free trial now. OptiNose Inc OPTN shares are trading higher Thursday after Paratek Pharmaceuticals announced a deal to acquire the company. What Happened: Late Wednesday ...

OptiNose (OPTN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $1.35 per share a year ago. These figures are ...

Click here for more https://monteverdelaw.com/case/optinose-inc-optn/. It is free and there is no cost or obligation to you. Acelyrin, Inc. (NASDAQ: SLRN), relating ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Optinose, Inc. (NASDAQ: OPTN) to Paratek Pharmaceuticals is fair to Optinose shareholders. Under the terms of ...